🇺🇸 FDA
Patent

US 10870855

Use of MIR101 or MIR128 in the treatment of seizure disorders

granted A61KA61K35/761A61K9/0019

Quick answer

US patent 10870855 (Use of MIR101 or MIR128 in the treatment of seizure disorders) held by OVID THERAPEUTICS INC. expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K35/761, A61K9/0019, A61K9/0085, A61K9/127